The use of low-dose aspirin in the prevention of pre-eclampsia: a literature review
Article Sidebar
Main Article Content
Abstract
Objective: To analyze the prophylactic use of low-dose aspirin, the importance of early diagnosis and its outcome at the end of pregnancy linked to the prevention of preeclampsia. Methods: The methodological approach proposes to describe through an integrative review. The databases used were the National Library of Medicine, Virtual Health Library and Cochrane Library. The descriptors used were: “pre-eclampsia”, “aspirin”, “pregnancy” and “risk factors”. Inclusion criteria were journal articles, clinical trials, clinical trials, randomized or non-randomized, case-control studies, cohort study, free access, published in English, Portuguese, Spanish, between 2012 and 2022. Results: The study analyzed women according to their high degree of risk for developing preeclampsia and evaluated low-dose aspirin prophylaxis. The risk factors that determined whether the pregnant woman had a high degree of preeclampsia (PE) varied between the articles, however, the most cited were: chronic hypertension, advanced age, previous history of preeclampsia, obesity, diabetes, thrombophilia, previous stillbirth, nulliparity, multifetal pregnancy, autoimmune disease and chronic kidney disease. Final considerations: Thus, prophylactic treatment with low doses of aspirin is currently performed, but further studies are still needed.
Article Details
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
References
2. BLOCK-ABRAHAM DM, et al. First-Trimester Risk Factors for Preeclampsia Development in Women Initiating Aspirin by 16 Weeks of Gestation. Obstetrics & Gynecology, 2014; 123(3): 611-617.
3. BOELIG RC, et al. Improving Utilization of Aspirin for Prevention of Preeclampsia in a High-Risk Urban Cohort: A Prospective Cohort Study. American Journal of Perinatology, 2021; 38(06): 544-552.
4. DIXON C, et al. Effect of Low-Dose Aspirin on the Time of Onset of Preeclampsia and Time of Delivery. American Journal of Perinatology, 2017; 34(12): 1219-1226.
5. GUY GP, et al. Implementação da triagem combinada de rotina no primeiro trimestre para pré-eclâmpsia: um estudo de eficácia clínica. BJOG: Um Jornal Internacional de Obstetrícia e Ginecologia, 2021; 128(2): 149-56.
6. HAUSPURG A, et al. Efeito da aspirina em resultados adversos da gravidez associados à hipertensão no estágio 1 em uma coorte de alto risco. Hipertensão, 2018; 72(1): 202-07.
7. HUAI J, et al. Efeito preventivo da aspirina na pré-eclâmpsia em mulheres grávidas de alto risco com hipertensão estágio 1. O Jornal de Hipertensão Clínica, 2021; 23(5): 1060-67.
8. LECARPENTIER E, HADDAD B. Aspirin for the prevention of placenta-mediated complications in pregnant women with chronic hypertension. Journal of Gynecology Obstetrics and Human Reproduction, 2020; 49(9): 101845.
9. LOURENÇO I, et al. Triagem para pré-eclâmpsia no primeiro trimestre e profilaxia com aspirina: nosso primeiro ano. Revista Brasileira de Ginecologia e Obstetrícia, 2020; 42: 390-96.
10. MONE F, et al. An open-label randomized-controlled trial of low dose aspirin with an early screening test for pre-eclampsia and growth restriction (TEST): Trial protocol. Contemporary Clinical Trials, 2016; 49: 143-148
11. MONTFORT P, et al. Uso de baixa dose de aspirina entre mulheres com risco aumentado de pré-eclâmpsia: um estudo de coorte prospectivo. Acta Obstetricia et Gynecologica Scandinavica, 2020; 99(7): 875-83.
12. ODIBO AO, et al. Estudo Previsão Precoce e Aspirina para Prevenção da Pré-Eclâmpsia (EPAPP): Um Ensaio Controlado Randomizado: Previsão Precoce e Aspirina para Prevenção da Pré-Eclâmpsia. Ultrassom em Obstetrícia e Ginecologia, 2015; 46(4): 414-18.
13. O'GORMAN N, et al. Protocolo de Estudo para o Ensaio Controlado Randomizado: Triagem Combinada de Multimarcadores e Tratamento Randomizado do Paciente com Aspirina para Prevenção da Pré-eclâmpsia Baseada em Evidências (ASPRE). BMJ Open, 2016; 6(6): e011801.
14. PARK F, et al. Previsão e Prevenção de Pré-Eclâmpsia de Início Precoce: Impacto da Aspirina após Triagem no Primeiro Trimestre. Ultrassom em Obstetrícia e Ginecologia, 2015; 46(4): 419-23.
15. POON LC, et al. Iniciativa da Federação Internacional de Ginecologia e Obstetrícia (FIGO) sobre Pré-Eclâmpsia: Um Guia Pragmático para Triagem e Prevenção no Primeiro Trimestre. Jornal Internacional de Ginecologia e Obstetrícia, 2019; 145(1): 1-33.
16. SHEN L, et al. ASPRE trial: risk factors for development of preterm pre-eclampsia despite aspirin prophylaxis. Ultrasound in Obstetrics and Gynecology, 2021; 58(4): 546-552.
17. STERN C, et al. Low Dose Aspirin in high-risk pregnancies: The volatile effect of acetylsalicylic acid on the inhibition of platelets uncovered by G. Born’s light transmission aggregometry. Journal of Reproductive Immunology, 2021; 145: 103320
18. WHEELER SM, et al. Prevalência estimada de fatores de risco para pré-eclâmpsia entre indivíduos que dão à luz nos EUA em 2019. JAMA Network Open, 2022; 5(1): e2142343.
19. WRIGHT D, NICOLAIDES KH. Aspirin delays the development of preeclampsia. American Journal of Obstetrics and Gynecology, 2019; 220(6): p580.E1-580.E6.
20. ZVANCA ME, et al. Impact of Early Supplementation with Low-Dose Aspirin on Functional First Trimester Parameters in Low-Risk Pregnancies. The Journal of Maternal-Fetal & Neonatal Medicine, 2019: 604-609.